Oxehealth Wins Funding to Trial Camera-based Health Monitoring with Broadmoor Hospital
News Dec 30, 2014
Oxehealth has been awarded funding by Innovate UK, to develop its vital sign monitoring technology, in collaboration with Broadmoor Hospital.
Oxehealth, the spin out from the University of Oxford’s Institute of Biomedical Engineering and Oxford University Hospitals NHS Trust, has received the funding to develop and test its Oxecam technology for monitoring the vital signs of patients in secure rooms.
The six-month project, which commenced on 1st October, is being run in conjunction with Broadmoor Hospital, the renowned high secure psychiatric hospital. If successful it will be followed by steps to develop a finished version of the Oxecam for secure rooms.
The use of the Oxecam is intended to improve the care of patients in secure rooms. It aims to improve their safety and well-being, and will save money by simplifying patient safety checks.
“In a world in which people are choosing to install and use cameras in ever more settings, Oxehealth’s technology will invisibly monitor personal health enabling us all to live safer, healthier and longer,” said Jonathan Chevallier, CEO at Oxehealth. “This trial at Broadmoor Hospital is a demonstration of how our technology works in secure environments, but it can equally be deployed in every home, vehicle and hospital worldwide.”
The project will test in a real-life setting how the Oxecam can improve upon the current approach of periodic observations by staff, which can be subject to inconsistencies or disturb the patients, especially at night. It will do this by using sophisticated algorithms to process video images and provide estimates of vital signs on a continuous basis.
The algorithms monitor the patient’s movement and breathing for signs of distress, as well as heart rate and other parameters that can be measured to assess the patient’s wellbeing.
“Using technology to improve the patient experience and to promote patient safety is exactly what all providers of healthcare are hoping to achieve”, said Dr Amlan Basu, Clinical Director at Broadmoor.
“We are enjoying working with the Oxehealth team on this project, not least due to our shared enthusiasm for this kind of innovative work. The potential to transfer this technology to other settings is also tremendously exciting.”
The project will be jointly run by Oxehealth and Broadmoor Hospital, with algorithm tuning supported by researchers at the Institute of Biomedical Engineering, University of Oxford.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018